DelveInsight’s “Huntington’s Illness Market Insights, Epidemiology, and Market Forecast-2036” report affords an in-depth understanding of Huntington’s illness, historic and forecasted epidemiology, in addition to Huntington’s Illness market developments throughout the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
To know extra concerning the Huntington’s Illness market outlook, drug uptake, remedy state of affairs, and epidemiology developments, go to: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Key Highlights from the Huntington’s Illness Market Report
• The Huntington’s Illness market was valued at roughly USD 320 million in 2025 and is projected to develop at a CAGR of round 14% throughout 2026-2036.
• AUSTEDO (Teva Prescribed drugs) generated the very best income amongst permitted therapies in 2025, contributing roughly USD 167 million.
• In September 2025, Skyhawk Therapeutics reported constructive interim Section I outcomes for SKY-0515, demonstrating dose-dependent reductions in mutant huntingtin (mHTT) protein.
• In January 2026, Skyhawk Therapeutics expanded the FALCON-HD Section II/III trial globally after encouraging nine-month interim outcomes, with greater than 90 sufferers handled.
• In March 2025, PTC Therapeutics introduced constructive Section II PIVOT-HD outcomes for Votoplam (PTC518), assembly its major endpoint for decreasing Huntingtin (HTT) protein ranges.
• In December 2024, Novartis entered a worldwide licensing and collaboration settlement with PTC Therapeutics for PTC518, a possible oral disease-modifying remedy.
• In Might 2024, the FDA permitted AUSTEDO XR, a once-daily remedy possibility for Huntington’s illness chorea.
• In August 2023, the FDA permitted INGREZZA (Neurocrine Biosciences) for chorea in adults with Huntington’s illness.
• The USA recorded roughly 44,000 prevalent Huntington’s illness circumstances in 2025, whereas the EU4 and the UK collectively reported roughly 37,000 circumstances.
• Throughout the 7MM, practically 50% of Huntington’s illness circumstances happen in people aged 60 years and above.
• Key corporations embody Teva Prescribed drugs, Neurocrine Biosciences, Novartis Prescribed drugs, Skyhawk Therapeutics, Alnylam Prescribed drugs, Roche, and UniQure Biopharma.
• Key therapies embody AUSTEDO, INGREZZA, SKY-0515, Votoplam (PTC518), Pridopidine, and ANX005.
• Amongst anticipated launches, INGREZZA and ANX005 (tanruprubart) are anticipated to seize vital market share through the forecast interval.
Huntington’s Illness Overview
Huntington’s illness is a uncommon, inherited, progressive neurodegenerative dysfunction brought on by a mutation within the HTT gene on chromosome 4. The mutation ends in the manufacturing of irregular huntingtin protein, resulting in gradual nerve cell injury within the mind.
The illness follows an autosomal dominant inheritance sample, that means every little one of an affected mother or father has a 50% likelihood of inheriting the mutation.
Frequent signs embody:
• Involuntary actions (chorea)
• Cognitive decline
• Melancholy and anxiousness
• Irritability and behavioral modifications
• Progressive lack of motor operate
Prognosis entails:
• Medical analysis
• Household historical past evaluation
• Genetic blood testing
• CT or MRI imaging
Whereas no treatment presently exists, out there remedies concentrate on symptom administration and supportive care all through illness development.
Get a free pattern of the Huntington’s Illness Market Report: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Huntington’s Illness Epidemiology Insights
The epidemiology part analyzes historic and projected affected person populations throughout the 7MM and identifies developments influencing illness burden by 2036.
In keeping with DelveInsight:
In the US, prevalent Huntington’s illness circumstances reached 44,000 in 2025 and are anticipated to extend through the forecast interval. EU4 and the UK collectively reported roughly 37,000 prevalent circumstances in 2025.
Extra epidemiology insights embody:
• Superior Stage IV and Stage V circumstances stay comparatively restricted, notably in Japan.
• Roughly 80 Stage IV and 20 Stage V circumstances had been estimated in Japan throughout 2025.
• People aged 60 years and older account for roughly half of all Huntington’s illness circumstances throughout the 7MM.
Epidemiology Segmentation
The report evaluates:
• Whole Prevalent Circumstances of Huntington’s Illness
• Whole Identified Prevalent Circumstances of Huntington’s Illness
• Age-Particular Circumstances of Huntington’s Illness
• Stage-Particular Circumstances of Huntington’s Illness
• Whole Handled Circumstances of Huntington’s Illness
Obtain the report back to discover Huntington’s Illness epidemiology developments: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Huntington’s Illness Therapies and Key Corporations
• AUSTEDO (deutetrabenazine) – Teva Prescribed drugs
• INGREZZA (valbenazine / NBI-98854) – Neurocrine Biosciences
• SKY-0515 – Skyhawk Therapeutics
• Votoplam (PTC518) – Novartis Prescribed drugs
• Pridopidine – Novartis Prescribed drugs
• ANX005 (tanruprubart) – Alnylam Prescribed drugs
Rising Huntington’s Illness Medication Uptake
The report analyzes the anticipated adoption of rising therapies between 2026 and 2036, together with anticipated affected person uptake and industrial efficiency.
Key pipeline therapies embody:
• SKY-0515: An oral RNA modulator developed utilizing Skyhawk’s SKYSTAR platform that reduces each HTT protein and PMS1 protein, focusing on illness development.
• Votoplam (PTC518): A small-molecule splicing modifier that promotes Huntingtin mRNA degradation and has demonstrated favorable security and dose-dependent HTT discount.
• ANX005 (tanruprubart): An investigational remedy anticipated to realize significant market share following potential approval.
The remedy panorama is steadily shifting from symptomatic administration towards gene-silencing and RNA-targeted disease-modifying therapies.
Uncover therapies anticipated to realize vital Huntington’s Illness market share: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Huntington’s Illness Market Forecast
The present Huntington’s Illness remedy panorama contains permitted therapies for chorea, akin to:
• AUSTEDO
• AUSTEDO XR
• INGREZZA
• Generic Tetrabenazine
These therapies primarily deal with signs relatively than slowing illness development.
Key Huntington’s Illness Market drivers embody:
• Developments in gene-silencing and RNA-based therapies.
• Improved consciousness and genetic testing enabling earlier prognosis.
• A powerful pipeline of disease-modifying therapies, together with SKY-0515 and Votoplam.
• Elevated funding in uncommon neurological problems.
• Favorable regulatory incentives, together with orphan drug designations and expedited approval pathways.
These components are anticipated to assist sustained market progress by 2036.
Scope of the Huntington’s Illness Market Report
• Examine Interval: 2022-2036
• Protection: 7MM (United States, EU4, United Kingdom, and Japan)
• Key Corporations: Teva Prescribed drugs, Neurocrine Biosciences, Novartis Prescribed drugs, Skyhawk Therapeutics, Alnylam Prescribed drugs, Roche, UniQure Biopharma, and others.
• Key Therapies: AUSTEDO, INGREZZA, SKY-0515, Votoplam (PTC518), Pridopidine, ANX005, and others.
• Therapeutic Evaluation: Present marketed and rising therapies.
• Market Dynamics: Drivers and boundaries.
• Aggressive Intelligence: SWOT Evaluation, PESTLE Evaluation, Porter’s 5 Forces, Conjoint Evaluation, and Market Entry Methods.
• Extra Insights: Unmet wants, KOL views, analyst views, market entry, and reimbursement evaluation.
Media Contact
Firm Identify: DelveInsight Enterprise Analysis LLP
Contact Individual: Mehul Malhotra
E-mail: information@delveinsight.com
Telephone: 09650213330
Deal with: 304 S. Jones Blvd #2432, Las Vegas, NV, United States
Web site: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a number one healthcare enterprise consulting and market analysis agency targeted completely on the life sciences sector. The corporate helps pharmaceutical, biotechnology, and medical machine organizations with complete market intelligence, aggressive evaluation, epidemiology forecasts, pipeline assessments, and strategic consulting providers to speed up enterprise progress and assist knowledgeable decision-making.
This launch was printed on openPR.
